NEW YORK (GenomeWeb) – GenomeDx Biosciences today announced that national Medicare benefit administration contractor Palmetto GBA has issued a positive coverage policy for the firm's Decipher prostate cancer classifier.

Palmetto issued the policy through the MolDx program, which it runs for the Centers for Medicare and Medicaid Services. In October 2014, Palmetto issued a preliminary local coverage determination for Decipher on behalf of CMS.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.